BACKGROUND Models for predicting hepatitis B e antigen(HBeAg)seroconversion in patients with HBeAg-positive chronic hepatitis B(CHB)after nucleos(t)ide analog treatment are rare.AIM To establish a simple scoring model...BACKGROUND Models for predicting hepatitis B e antigen(HBeAg)seroconversion in patients with HBeAg-positive chronic hepatitis B(CHB)after nucleos(t)ide analog treatment are rare.AIM To establish a simple scoring model based on a response-guided therapy(RGT)strategy for predicting HBeAg seroconversion and hepatitis B surface antigen(HBsAg)clearance.METHODS In this study,75 previously treated patients with HBeAg-positive CHB underwent a 52-week peginterferon-alfa(PEG-IFNα)treatment and a 24-wk follow-up.Logistic regression analysis was used to assess parameters at baseline,week 12,and week 24 to predict HBeAg seroconversion at 24 wk post-treatment.The two best predictors at each time point were used to establish a prediction model for PEG-IFNαtherapy efficacy.Parameters at each time point that met the corresponding optimal cutoff thresholds were scored as 1 or 0.RESULTS The two most meaningful predictors were HBsAg≤1000 IU/mL and HBeAg≤3 S/CO at baseline,HBsAg≤600 IU/mL and HBeAg≤3 S/CO at week 12,and HBsAg≤300 IU/mL and HBeAg≤2 S/CO at week 24.With a total score of 0 vs 2 at baseline,week 12,and week 24,the response rates were 23.8%,15.2%,and 11.1%vs 81.8%,80.0%,and 82.4%,respectively,and the HBsAg clearance rates were 2.4%,3.0%,and 0.0%,vs 54.5%,40.0%,and 41.2%,respectively.CONCLUSION We successfully established a predictive model and diagnosis-treatment process using the RGT strategy to predict HBeAg and HBsAg seroconversion in patients with HBeAg-positive CHB undergoing PEG-IFNαtherapy.展开更多
Poor conductivity,sluggish ion diffusion kinetics and short cycle life hinder the further development of manganese oxide in aqueous zinc-ion batteries(AZIBs).Exploring a cathode with high capacity and long cycle life ...Poor conductivity,sluggish ion diffusion kinetics and short cycle life hinder the further development of manganese oxide in aqueous zinc-ion batteries(AZIBs).Exploring a cathode with high capacity and long cycle life is critical to the commercial development of AZIBs.Herein,a two-dimensional(2D) MnO/C composite derived from metal organic framework(MOF) was prepared.The 2D MnO/C cathode exhibits a remarkably cyclic stability with the capacity retention of 90.6% after 900 cycles at 0.5 A·g^(-1) and maintains a high capacity of 120.2 mAh·g^(-1)after 4500 cycles at 1.0 A·g^(-1).It is demonstrated that MnO is converted into Mn_(3)O_(4) through electrochemical activation strategy and shows a Zn^(2+)and H^(+)co-intercalation mechanism.In general,this work provides a new path for the development of high-performance AZIBs cathode with controllable morphology.展开更多
基金Supported by the Anhui Provincial Natural Science Foundation,No.2108085MH298the Scientific Research Project of the Second Affiliated Hospital of Anhui Medical University,No.2019GMFY02 and 2021lcxk027the Scientific Research Project of Colleges and Universities in Anhui Province,No.KJ2021A0323.
文摘BACKGROUND Models for predicting hepatitis B e antigen(HBeAg)seroconversion in patients with HBeAg-positive chronic hepatitis B(CHB)after nucleos(t)ide analog treatment are rare.AIM To establish a simple scoring model based on a response-guided therapy(RGT)strategy for predicting HBeAg seroconversion and hepatitis B surface antigen(HBsAg)clearance.METHODS In this study,75 previously treated patients with HBeAg-positive CHB underwent a 52-week peginterferon-alfa(PEG-IFNα)treatment and a 24-wk follow-up.Logistic regression analysis was used to assess parameters at baseline,week 12,and week 24 to predict HBeAg seroconversion at 24 wk post-treatment.The two best predictors at each time point were used to establish a prediction model for PEG-IFNαtherapy efficacy.Parameters at each time point that met the corresponding optimal cutoff thresholds were scored as 1 or 0.RESULTS The two most meaningful predictors were HBsAg≤1000 IU/mL and HBeAg≤3 S/CO at baseline,HBsAg≤600 IU/mL and HBeAg≤3 S/CO at week 12,and HBsAg≤300 IU/mL and HBeAg≤2 S/CO at week 24.With a total score of 0 vs 2 at baseline,week 12,and week 24,the response rates were 23.8%,15.2%,and 11.1%vs 81.8%,80.0%,and 82.4%,respectively,and the HBsAg clearance rates were 2.4%,3.0%,and 0.0%,vs 54.5%,40.0%,and 41.2%,respectively.CONCLUSION We successfully established a predictive model and diagnosis-treatment process using the RGT strategy to predict HBeAg and HBsAg seroconversion in patients with HBeAg-positive CHB undergoing PEG-IFNαtherapy.
基金financially supported by the National Natural Science Foundation of China (Nos.22078200 and 51874199)Guangdong Basic and Applied Basic Research Foundation (No.2021A1515010162)。
文摘Poor conductivity,sluggish ion diffusion kinetics and short cycle life hinder the further development of manganese oxide in aqueous zinc-ion batteries(AZIBs).Exploring a cathode with high capacity and long cycle life is critical to the commercial development of AZIBs.Herein,a two-dimensional(2D) MnO/C composite derived from metal organic framework(MOF) was prepared.The 2D MnO/C cathode exhibits a remarkably cyclic stability with the capacity retention of 90.6% after 900 cycles at 0.5 A·g^(-1) and maintains a high capacity of 120.2 mAh·g^(-1)after 4500 cycles at 1.0 A·g^(-1).It is demonstrated that MnO is converted into Mn_(3)O_(4) through electrochemical activation strategy and shows a Zn^(2+)and H^(+)co-intercalation mechanism.In general,this work provides a new path for the development of high-performance AZIBs cathode with controllable morphology.
